<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00591825</url>
  </required_header>
  <id_info>
    <org_study_id>10362</org_study_id>
    <secondary_id>GCRC 0046</secondary_id>
    <secondary_id>HSCL 15970</secondary_id>
    <nct_id>NCT00591825</nct_id>
  </id_info>
  <brief_title>fMRI Study Examining Effects of D-cycloserine in Specific Phobia</brief_title>
  <official_title>An fMRI Study Investigating the Effects of Acute D-cycloserine Administration on Brain Activations and Cognitive Functioning in Spider Phobia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Psychological Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nepalese Psychological Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The research team hopes to use brain imaging and mental testing to learn more about specific
      phobias and the treatment of phobia. When given directly prior to therapy sessions,
      D-cycloserine has been shown to enhance the effects of therapy. This study hopes to identify
      reasons why D-cycloserine has this effect by measuring brain activity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Exposure and Response Prevention (ERP) therapy has become the treatment of choice for
      specific phobias. ERP involves systematic and repeated exposure to a feared or
      anxiety-provoking stimulus, leading to habituation and extinction of the fear response.
      Animal models of fear extinction have shown that acute administration of D-cycloserine (DCS)
      prior to exposure to a feared stimulus enhances extinction of that fear. A recent study in
      human subjects with height phobia (a specific phobia) has also demonstrated that DCS
      facilitates the effects of ERP therapy. Current theories postulate that DCS facilitates fear
      extinction by enhancing the learning process and increasing consolidation of memories, but
      the neural mechanisms underlying this process are not understood. The proposed research aims
      to elucidate these mechanisms by using fMRI to measure brain activation during 1) symptom
      provocation and verbal learning two hours post-medication, and 2)repeated symptom provocation
      and verbal recognition one week post-medication. This research will also examine the effects
      of DCS on cognitive functioning using neuropsychological testing both two house and one week
      post-medication.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fMRI Brain Activations During Symptom Provocation</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Regions of interest (ROIs) were specified based on previous research and included amygdala, insula, dorsal anterior cingulate cortex (ACC), dorsolateral PFC (dlPFC), and hippocampus. Multiple regression analyses were used to examine differences in response between experimental conditions (spider versus butterfly images). For significant clusters of activation within ROIs, the average max percent signal change is reported. For other regions, the average max percent signal change is reported within a sphere centered at coordinates identified via previous research.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests)</measure>
    <time_frame>2 Weeks</time_frame>
    <description>This scale measures the learning and memory of functioning adults. Logical Memory I and II and Faces I and II subtests were administered to participants. The tasks measure verbal and visual memory, respectively. Scoring is based on the number of story details or faces correctly recalled during immediate (Logical Memory I, Faces I) and 30 minute delayed (Logical Memory II, Faces II) conditions. Total score ranges from 0-75 on Logical Memory I, 0-50 on Logical Memory II, 0-48 on Faces I, and 0-48 on Faces II. For all subtests, higher scores indicate better memory performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT)</measure>
    <time_frame>2 weeks</time_frame>
    <description>The RCFT assesses the a person's ability to use cues to retrieve information. The test measures visuospatial construction and memory. A person is asked to draw a figure. The figure is broken down into 18 elements. The score is based on their presence, completeness, and correct placement. Each element is scored from 0-2. The Copy, Immediate, and Delay results are scored on a 36 point scale. The higher the score, the better the person performed on the test with a 0 being the minimum and 36 being the maximum score. The organization score is scored according to whether the participant drew five cohesive units of the figure together, for a range of 0-6 and a higher score indicating better organizational performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Functioning Measured Using the Iowa Gambling Test</measure>
    <time_frame>2 weeks</time_frame>
    <description>This test measures a person's emotional decision making. Participants are presented with virtual decks of cards on a computer. Participants are told that each card they draw will &quot;win&quot; them game money. However, sometimes cards result in &quot;losing&quot; game money. The task includes 100 trials and the total score represents the number of cards drawn from &quot;bad&quot; decks as compared to &quot;good&quot; or safe decks. Thus, the score ranges from -100 to +100, with higher sores representing better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Functioning Measured Using the Wisconsin Card Sorting Task</measure>
    <time_frame>2 weeks</time_frame>
    <description>The Wisconsin Card Sorting Task measures executive functioning and cognitive flexibility. The task uses a deck of 64 cards that the participant must sort according to specified rules. The test is stopped when when six sequences of 10 correct responses have been achieved, or after the deck has been completed twice, which provides a cumulative total of 128 trials. We report the number of errors on the task, which has a range of 0 -128, with a higher score representing worse performance.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Phobias</condition>
  <arm_group>
    <arm_group_label>Non-Phobic Control - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants without phobia will be given one placebo administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Phobic Control - DCS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants without phobia will be given one D-cycloserine (DCS) administration of 100mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spider-phobic Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants with phobia will be given one placebo administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spider-phobic DCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with phobia will be given one D-cycloserine (DCS) administration of 100mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-cycloserine</intervention_name>
    <description>D-cycloserine</description>
    <arm_group_label>Non-Phobic Control - DCS</arm_group_label>
    <arm_group_label>Spider-phobic DCS</arm_group_label>
    <other_name>Cycloserine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Non-Phobic Control - Placebo</arm_group_label>
    <arm_group_label>Spider-phobic Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Right-handed

          -  Adults between 18 and 55 years of age

          -  Subjects in the phobic group will additionally meet diagnostic (DSM-IV) criteria for
             spider phobia.

          -  Individuals of both genders and all races will be included

        Exclusion Criteria:

          -  Women who are breastfeeding or pregnant

          -  Individuals with medical conditions unsuitable for MR scanning

          -  Individuals reporting a history of epilepsy or seizures

          -  Individuals reporting an allergy to cycloserine

          -  Individuals diagnosed with asthma or who report previous anaphylactic reaction to
             insect stings/bites, medication, food, or other material and/or event

          -  Individuals reporting present or past diagnosis of a developmental disorder,
             neurological disorder, or head injury *Individuals found to have Axis I
             psychopathology as defined by the DSM-IV (other than spider phobia)

          -  Individuals currently taking any psychotropic medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cary Savage, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center, Hoglund Brain Imaging Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2007</study_first_submitted>
  <study_first_submitted_qc>January 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2008</study_first_posted>
  <results_first_submitted>October 29, 2015</results_first_submitted>
  <results_first_submitted_qc>June 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 5, 2017</results_first_posted>
  <last_update_submitted>June 1, 2017</last_update_submitted>
  <last_update_submitted_qc>June 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas</investigator_affiliation>
    <investigator_full_name>Cary Savage, Ph.D.</investigator_full_name>
    <investigator_title>Director, CHBN and John H. Wineinger Professor of Psychiatry and Behavioral Sciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phobic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cycloserine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Non-Phobic Control - Placebo</title>
          <description>Participants without phobia given one administration placebo.</description>
        </group>
        <group group_id="P2">
          <title>Non-Phobic Control - DCS</title>
          <description>Participants without phobia given one administration of 100 mg D-cycloserine (DCS).</description>
        </group>
        <group group_id="P3">
          <title>Spider-phobic Placebo</title>
          <description>Participants with phobia given one administration of placebo.</description>
        </group>
        <group group_id="P4">
          <title>Spider-phobic DCS</title>
          <description>Participants with phobia given one administration of 100 mg D-cycloserine (DCS).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Non-Phobic Control - Placebo</title>
          <description>Participants without phobia given one administration of placebo.</description>
        </group>
        <group group_id="B2">
          <title>Non-Phobic Control - DCS</title>
          <description>Participants without phobia given one administration of 100 mg D-cycloserine (DCS).</description>
        </group>
        <group group_id="B3">
          <title>Spider-phobic Placebo</title>
          <description>Participants with phobia given one administration of placebo.</description>
        </group>
        <group group_id="B4">
          <title>Spider-phobic DCS</title>
          <description>Participants with phobia given one administration of 100 mg D-cycloserine (DCS).</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="14"/>
            <count group_id="B5" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.09" spread="3.70"/>
                    <measurement group_id="B2" value="26.75" spread="9.09"/>
                    <measurement group_id="B3" value="26.00" spread="8.06"/>
                    <measurement group_id="B4" value="24.73" spread="6.65"/>
                    <measurement group_id="B5" value="25.65" spread="7.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>fMRI Brain Activations During Symptom Provocation</title>
        <description>Regions of interest (ROIs) were specified based on previous research and included amygdala, insula, dorsal anterior cingulate cortex (ACC), dorsolateral PFC (dlPFC), and hippocampus. Multiple regression analyses were used to examine differences in response between experimental conditions (spider versus butterfly images). For significant clusters of activation within ROIs, the average max percent signal change is reported. For other regions, the average max percent signal change is reported within a sphere centered at coordinates identified via previous research.</description>
        <time_frame>2 Weeks</time_frame>
        <population>There were 54 enrolled in the study. 8 subjects were excluded from fMRI analyses: 1 for claustrophobia, 3 for scanner artifact, 1 because of motion &gt;3mm; 3 of paradigm-consistent motion which could not be corrected for.</population>
        <group_list>
          <group group_id="O1">
            <title>DCS Phobic</title>
            <description>Participants with phobia who were randomized to the DCS group were given one administration of 100 mg D-cycloserine (DCS).</description>
          </group>
          <group group_id="O2">
            <title>DCS Control</title>
            <description>Participants without phobia who were randomized to the DCS group were given one administration of 100 mg D-cycloserine (DCS).</description>
          </group>
          <group group_id="O3">
            <title>Placebo Phobic</title>
            <description>Participants with phobia who were randomized to the Placebo group were given one administration of placebo.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Control</title>
            <description>Participants without phobia who were randomized to the Placebo group were given one administration of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>fMRI Brain Activations During Symptom Provocation</title>
          <description>Regions of interest (ROIs) were specified based on previous research and included amygdala, insula, dorsal anterior cingulate cortex (ACC), dorsolateral PFC (dlPFC), and hippocampus. Multiple regression analyses were used to examine differences in response between experimental conditions (spider versus butterfly images). For significant clusters of activation within ROIs, the average max percent signal change is reported. For other regions, the average max percent signal change is reported within a sphere centered at coordinates identified via previous research.</description>
          <population>There were 54 enrolled in the study. 8 subjects were excluded from fMRI analyses: 1 for claustrophobia, 3 for scanner artifact, 1 because of motion &gt;3mm; 3 of paradigm-consistent motion which could not be corrected for.</population>
          <units>percent signal change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Left Insula Spider</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".200" spread=".182"/>
                    <measurement group_id="O2" value=".157" spread=".373"/>
                    <measurement group_id="O3" value="-.013" spread=".167"/>
                    <measurement group_id="O4" value=".036" spread=".095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Insula Butterfly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".012" spread=".139"/>
                    <measurement group_id="O2" value=".021" spread=".376"/>
                    <measurement group_id="O3" value=".092" spread=".162"/>
                    <measurement group_id="O4" value=".079" spread=".147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Insula Spider</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".107" spread=".190"/>
                    <measurement group_id="O2" value=".174" spread=".287"/>
                    <measurement group_id="O3" value="-.004" spread=".087"/>
                    <measurement group_id="O4" value=".020" spread=".250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Insula Butterfly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".017" spread=".144"/>
                    <measurement group_id="O2" value=".109" spread=".221"/>
                    <measurement group_id="O3" value=".133" spread=".139"/>
                    <measurement group_id="O4" value=".017" spread=".211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mid dorsal ACC Spider</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".242" spread=".135"/>
                    <measurement group_id="O2" value=".402" spread=".459"/>
                    <measurement group_id="O3" value=".073" spread=".171"/>
                    <measurement group_id="O4" value=".071" spread=".180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mid dorsal ACC Butterfly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".022" spread=".114"/>
                    <measurement group_id="O2" value=".053" spread=".166"/>
                    <measurement group_id="O3" value=".085" spread=".123"/>
                    <measurement group_id="O4" value="-.059" spread=".244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left dlPFC Spider</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".250" spread=".183"/>
                    <measurement group_id="O2" value=".122" spread=".361"/>
                    <measurement group_id="O3" value=".019" spread=".118"/>
                    <measurement group_id="O4" value=".278" spread=".300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left dlPFC Butterfly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".031" spread=".122"/>
                    <measurement group_id="O2" value=".076" spread=".372"/>
                    <measurement group_id="O3" value=".035" spread=".154"/>
                    <measurement group_id="O4" value=".075" spread=".435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right dlPFC Spider</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".384" spread=".286"/>
                    <measurement group_id="O2" value=".521" spread=".676"/>
                    <measurement group_id="O3" value=".301" spread=".349"/>
                    <measurement group_id="O4" value=".038" spread=".464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right dlPFC Butterfly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".150" spread=".203"/>
                    <measurement group_id="O2" value=".431" spread=".585"/>
                    <measurement group_id="O3" value=".249" spread=".420"/>
                    <measurement group_id="O4" value=".110" spread=".310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left amygdala Spider</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".322" spread=".182"/>
                    <measurement group_id="O2" value=".202" spread=".308"/>
                    <measurement group_id="O3" value=".534" spread=".272"/>
                    <measurement group_id="O4" value=".427" spread=".244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left amygdala Butterfly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".127" spread=".139"/>
                    <measurement group_id="O2" value=".149" spread=".137"/>
                    <measurement group_id="O3" value=".254" spread=".157"/>
                    <measurement group_id="O4" value=".098" spread=".299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right amygdala Spider</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".241" spread=".157"/>
                    <measurement group_id="O2" value=".155" spread=".347"/>
                    <measurement group_id="O3" value=".183" spread=".336"/>
                    <measurement group_id="O4" value=".133" spread=".230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right amygdala Butterfly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".082" spread=".157"/>
                    <measurement group_id="O2" value=".181" spread=".244"/>
                    <measurement group_id="O3" value=".203" spread=".216"/>
                    <measurement group_id="O4" value="-.017" spread=".273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left hippocampus Spider</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".101" spread=".222"/>
                    <measurement group_id="O2" value=".196" spread=".217"/>
                    <measurement group_id="O3" value=".185" spread=".184"/>
                    <measurement group_id="O4" value=".131" spread=".206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left hippocampus Butterfly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".010" spread=".180"/>
                    <measurement group_id="O2" value=".065" spread=".112"/>
                    <measurement group_id="O3" value=".204" spread=".170"/>
                    <measurement group_id="O4" value=".086" spread=".158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right hippocampus Spider</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".113" spread=".315"/>
                    <measurement group_id="O2" value=".310" spread=".224"/>
                    <measurement group_id="O3" value=".075" spread=".193"/>
                    <measurement group_id="O4" value=".361" spread=".347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right hippocampus Butterfly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".017" spread=".103"/>
                    <measurement group_id="O2" value=".219" spread=".203"/>
                    <measurement group_id="O3" value=".155" spread=".118"/>
                    <measurement group_id="O4" value=".329" spread=".283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests)</title>
        <description>This scale measures the learning and memory of functioning adults. Logical Memory I and II and Faces I and II subtests were administered to participants. The tasks measure verbal and visual memory, respectively. Scoring is based on the number of story details or faces correctly recalled during immediate (Logical Memory I, Faces I) and 30 minute delayed (Logical Memory II, Faces II) conditions. Total score ranges from 0-75 on Logical Memory I, 0-50 on Logical Memory II, 0-48 on Faces I, and 0-48 on Faces II. For all subtests, higher scores indicate better memory performance.</description>
        <time_frame>2 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-Phobic Control - Placebo</title>
            <description>Participants without phobia given one administration of placebo.</description>
          </group>
          <group group_id="O2">
            <title>Non-Phobic Control - DCS</title>
            <description>Participants without phobia given one administration of 100 mg D-cycloserine (DCS).</description>
          </group>
          <group group_id="O3">
            <title>Spider-phobic Placebo</title>
            <description>Participants with phobia given one administration of placebo.</description>
          </group>
          <group group_id="O4">
            <title>Spider-phobic DCS</title>
            <description>Participants without phobia given one administration of 100 mg D-cycloserine.</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests)</title>
          <description>This scale measures the learning and memory of functioning adults. Logical Memory I and II and Faces I and II subtests were administered to participants. The tasks measure verbal and visual memory, respectively. Scoring is based on the number of story details or faces correctly recalled during immediate (Logical Memory I, Faces I) and 30 minute delayed (Logical Memory II, Faces II) conditions. Total score ranges from 0-75 on Logical Memory I, 0-50 on Logical Memory II, 0-48 on Faces I, and 0-48 on Faces II. For all subtests, higher scores indicate better memory performance.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Logical Memory 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.93" spread="8.91"/>
                    <measurement group_id="O2" value="49" spread="9.24"/>
                    <measurement group_id="O3" value="52.69" spread="10.30"/>
                    <measurement group_id="O4" value="52.93" spread="7.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Logical Memory 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.36" spread="6.67"/>
                    <measurement group_id="O2" value="32.46" spread="7.03"/>
                    <measurement group_id="O3" value="34.85" spread="8.21"/>
                    <measurement group_id="O4" value="35.43" spread="5.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Faces 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.43" spread="3.2"/>
                    <measurement group_id="O2" value="41.85" spread="2.73"/>
                    <measurement group_id="O3" value="41" spread="4.28"/>
                    <measurement group_id="O4" value="42.07" spread="3.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Faces 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.93" spread="2.09"/>
                    <measurement group_id="O2" value="41.62" spread="2.99"/>
                    <measurement group_id="O3" value="41.62" spread="3.43"/>
                    <measurement group_id="O4" value="42.07" spread="3.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT)</title>
        <description>The RCFT assesses the a person’s ability to use cues to retrieve information. The test measures visuospatial construction and memory. A person is asked to draw a figure. The figure is broken down into 18 elements. The score is based on their presence, completeness, and correct placement. Each element is scored from 0-2. The Copy, Immediate, and Delay results are scored on a 36 point scale. The higher the score, the better the person performed on the test with a 0 being the minimum and 36 being the maximum score. The organization score is scored according to whether the participant drew five cohesive units of the figure together, for a range of 0-6 and a higher score indicating better organizational performance.</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-Phobic Control - Placebo</title>
            <description>Participants without phobia given one administration of placebo.</description>
          </group>
          <group group_id="O2">
            <title>Non-Phobic Control - DCS</title>
            <description>Participants without phobia given one administration of 100 mg D-cycloserine (DCS).</description>
          </group>
          <group group_id="O3">
            <title>Spider-phobic Placebo</title>
            <description>Participants with phobia given one administration of placebo.</description>
          </group>
          <group group_id="O4">
            <title>Spider-phobic DCS</title>
            <description>Participants with phobia given one administration of 100 mg D-cycloserine (DCS).</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT)</title>
          <description>The RCFT assesses the a person’s ability to use cues to retrieve information. The test measures visuospatial construction and memory. A person is asked to draw a figure. The figure is broken down into 18 elements. The score is based on their presence, completeness, and correct placement. Each element is scored from 0-2. The Copy, Immediate, and Delay results are scored on a 36 point scale. The higher the score, the better the person performed on the test with a 0 being the minimum and 36 being the maximum score. The organization score is scored according to whether the participant drew five cohesive units of the figure together, for a range of 0-6 and a higher score indicating better organizational performance.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Organization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.93" spread="1.33"/>
                    <measurement group_id="O2" value="4.92" spread="1.55"/>
                    <measurement group_id="O3" value="3.69" spread="1.97"/>
                    <measurement group_id="O4" value="4.14" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Copy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.68" spread="2.49"/>
                    <measurement group_id="O2" value="34.46" spread="3.53"/>
                    <measurement group_id="O3" value="34.46" spread="2.15"/>
                    <measurement group_id="O4" value="34.50" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immediate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.54" spread="3.97"/>
                    <measurement group_id="O2" value="24.77" spread="6.66"/>
                    <measurement group_id="O3" value="26.17" spread="3.76"/>
                    <measurement group_id="O4" value="26.14" spread="5.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Delay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.08" spread="3.81"/>
                    <measurement group_id="O2" value="23.35" spread="7.11"/>
                    <measurement group_id="O3" value="26.13" spread="2.57"/>
                    <measurement group_id="O4" value="25.64" spread="5.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cognitive Functioning Measured Using the Iowa Gambling Test</title>
        <description>This test measures a person's emotional decision making. Participants are presented with virtual decks of cards on a computer. Participants are told that each card they draw will &quot;win&quot; them game money. However, sometimes cards result in &quot;losing&quot; game money. The task includes 100 trials and the total score represents the number of cards drawn from &quot;bad&quot; decks as compared to &quot;good&quot; or safe decks. Thus, the score ranges from -100 to +100, with higher sores representing better performance.</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-Phobic Control - Placebo</title>
            <description>Participants without phobia were given one administration placebo.</description>
          </group>
          <group group_id="O2">
            <title>Non-Phobic Control - DCS</title>
            <description>Participants without phobia were given one administration 100 mg D-cycloserine (DCS).</description>
          </group>
          <group group_id="O3">
            <title>Spider-phobic Placebo</title>
            <description>Participants with phobia were given one administration placebo.</description>
          </group>
          <group group_id="O4">
            <title>Spider-phobic DCS</title>
            <description>Participants with phobia were given one administration 100 mg placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Functioning Measured Using the Iowa Gambling Test</title>
          <description>This test measures a person's emotional decision making. Participants are presented with virtual decks of cards on a computer. Participants are told that each card they draw will &quot;win&quot; them game money. However, sometimes cards result in &quot;losing&quot; game money. The task includes 100 trials and the total score represents the number of cards drawn from &quot;bad&quot; decks as compared to &quot;good&quot; or safe decks. Thus, the score ranges from -100 to +100, with higher sores representing better performance.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.29" spread="23.68"/>
                    <measurement group_id="O2" value="32.62" spread="26.76"/>
                    <measurement group_id="O3" value="28.58" spread="21.89"/>
                    <measurement group_id="O4" value="21.85" spread="28.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cognitive Functioning Measured Using the Wisconsin Card Sorting Task</title>
        <description>The Wisconsin Card Sorting Task measures executive functioning and cognitive flexibility. The task uses a deck of 64 cards that the participant must sort according to specified rules. The test is stopped when when six sequences of 10 correct responses have been achieved, or after the deck has been completed twice, which provides a cumulative total of 128 trials. We report the number of errors on the task, which has a range of 0 -128, with a higher score representing worse performance.</description>
        <time_frame>2 weeks</time_frame>
        <population>Two subjects did not complete the test because they had previous exposure to the test.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Phobic Control - Placebo</title>
            <description>Participants without phobia were given one administration placebo.</description>
          </group>
          <group group_id="O2">
            <title>Non-Phobic Control - DCS</title>
            <description>Participants without phobia were given one administration 100 mg D-cycloserine (DCS).</description>
          </group>
          <group group_id="O3">
            <title>Spider-phobic Placebo</title>
            <description>Participants with phobia were given one administration placebo.</description>
          </group>
          <group group_id="O4">
            <title>Spider-phobic DCS</title>
            <description>Participants with phobia were given one administration 100 mg D-cycloserine (DCS).</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Functioning Measured Using the Wisconsin Card Sorting Task</title>
          <description>The Wisconsin Card Sorting Task measures executive functioning and cognitive flexibility. The task uses a deck of 64 cards that the participant must sort according to specified rules. The test is stopped when when six sequences of 10 correct responses have been achieved, or after the deck has been completed twice, which provides a cumulative total of 128 trials. We report the number of errors on the task, which has a range of 0 -128, with a higher score representing worse performance.</description>
          <population>Two subjects did not complete the test because they had previous exposure to the test.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.29" spread="6.98"/>
                    <measurement group_id="O2" value="13.62" spread="7.65"/>
                    <measurement group_id="O3" value="18.23" spread="16.58"/>
                    <measurement group_id="O4" value="15.67" spread="9.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>At the end of each session, approximately 4-6 hours after drug administration. Participants were monitored through study completion, an average of 1 week.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Non-Phobic Control - Placebo</title>
          <description>Participants without phobia were given one administration placebo.</description>
        </group>
        <group group_id="E2">
          <title>Non-Phobic Control - DCS</title>
          <description>Participants without phobia were given one administration 100 mg D-cycloserine (DCS).</description>
        </group>
        <group group_id="E3">
          <title>Spider-phobic Placebo</title>
          <description>Participants with phobia were given one administration placebo.</description>
        </group>
        <group group_id="E4">
          <title>Spider-phobic DCS</title>
          <description>Participants with phobia were given one administration 100 mg D-cycloserine (DCS).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robin Aupperle, PhD</name_or_title>
      <organization>Laureate Institute for Brain Research (LIBR)</organization>
      <phone>(913) 588-9078</phone>
      <email>raupperle@laureateinstitute.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

